429 Results (Page 18 of 18)
Spain Markets Research Reports
Spain Actinic Keratosis Therapeutic Market Analysis
The Spain Actinic Keratosis Therapeutics Market was valued at $131 Mn in 2023 and is expected to reach $178 Mn by 2030, growing at a CAGR of 3.9%. The Spain Actinic Keratosis Therapeutics Market presents a promising outlook with rising prevalence, increasing public awareness campaigns to educate individuals about risks and the importance of early detection, increasing focus on early intervention, and development of novel treatment options. Major pharmaceutical companies like Bayer, Galderma, Pierre Fabre, Chemiplastics, Oncopharma, etc hold significant market shares
Spain Blood Disorder Therapeutics Market
Spain Blood Disorder Therapeutics Market valued at $259 Mn in 2022, projected to reach $428 Mn by 2030 with a 6.5% CAGR. The key drivers of the Spanish market include the aging population leading to a higher prevalence of blood-related issues, technological advancements like gene editing technologies creating new treatment opportunities, and evolving healthcare dynamics such as policies supporting early diagnosis and access to innovative medicines. The Spain Blood Disorder Therapeutics Market encompasses various players across different segments, including Novartis, Pfizer, Roche, Sanofi, Takeda, Bristol-Myers Squibb, Grifols, Gilead Sciences, Janssen Pharmaceuticals, BioMarin Pharmaceuticals etc, among various others.
Spain Cancer Induced Bone Disease Therapeutics Market
Spain Cancer Induced Bone Disease Therapeutics Market valued at $25 Mn in 2022, projected to reach $37 Mn by 2030 with a 4.8% CAGR. The key drivers of this industry include the increase in the incidence of cancers, unmet medical needs, and technological advancements. The industry is primarily dominated by players such as Advaxis, Takeda, Gradalis, Roche, Eli Lilly, Hikma, Bayer, and Amgen among others.
Spain Cardiac Resynchronization Therapy Market
Spain Cardiac Resynchronization Therapy Market valued at $93 Mn in 2022, projected to reach $127 Mn by 2030 with a 4% CAGR. The worldwide increase in heart failure instances, propelled by aging demographics and cardiovascular diseases linked to lifestyle, stands as a pivotal factor fuelling the growth of the Cardiac Resynchronization Therapy (CRT) market. Presently, key players in this market encompass Abbott, Boston Scientific, Medtronic, Biotronik, Siemens Healthineers, St. Jude Medical, Sorin Group, Edwards Lifesciences, LivaNova, and Terumo.